# children with achondroplasia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/children-with-achondroplasia

> No upcoming FDA catalysts in children with achondroplasia; 4 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 31, 2025 | [YUVIWEL® (navepegritide) NDA/BLA acceptance](https://sec-api.dev/pdufa/navepegritide) | ASND | children with achondroplasia | completed | "We submitted a New Drug Application ("NDA") for the treatment of children with achondroplasia on March 31, 2025 and the FDA has accepted for priority review our NDA for TransCon CNP (navepegritide)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312526063954/d112586dex992.htm)) |
| March 31, 2025 | [YUVIWEL® (navepegritide) NDA/BLA submission](https://sec-api.dev/pdufa/navepegritide) | ASND | children with achondroplasia | completed | "On March 31, 2025, the Company announced that it has submitted its New Drug Application to the U.S. Food & Drug Administration for TransCon CNP (navepegritide) for the treatment of children with achondroplasia." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312525068722/d923652d6k.htm)) |
| November 30, 2025 | [YUVIWEL® (navepegritide) PDUFA date](https://sec-api.dev/pdufa/navepegritide) | ASND | children with achondroplasia | delayed | "TransCon® CNP (navepegritide) under FDA Priority Review for the treatment of children with achondroplasia with PDUFA date of November 30, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1612042/000119312525277532/d88973dex991.htm)) |
| October 6, 2026 | [TRUSELTIQ® (infigratinib) NDA/BLA acceptance](https://sec-api.dev/pdufa/infigratinib) | BBIO | children with achondroplasia | completed | "PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced the FDA has accepted for filing its New Drug Application (NDA) with Priority Review for oral infigratinib for the treatment of children with achondroplasia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000114036126039334/ef20083591_ex99-1.htm)) |

## Drugs

- [YUVIWEL® (navepegritide)](https://sec-api.dev/pdufa/navepegritide) (ASND)
- [TRUSELTIQ® (infigratinib)](https://sec-api.dev/pdufa/infigratinib) (BBIO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/children-with-achondroplasia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "children with achondroplasia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/children-with-achondroplasia

```bibtex
@misc{secapidev_indications_children_with_achondroplasia_20261116,
  title        = {children with achondroplasia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/children-with-achondroplasia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_children_with_achondroplasia_20261116","title":"children with achondroplasia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/children-with-achondroplasia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
